Projects funded by the NCN
Drug repurposing to target p53 protein family for improved therapy in the relapsed TP53 and EGFR mutated lung cancer
2020/39/B/NZ7/00757
Keywords:
drug repurposing p53 p73 apoptosis tumor suppression mutant p53 drug combinations
Descriptors:
- NZ7_014:
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Warszawski Uniwersytet Medyczny
woj. mazowieckie
Principal investigator (from the host institution):
dr Joanna Elżbieta Zawacka-Pankau
Number of co-investigators in the project: 4
Call: OPUS 20 - announced on 2020-09-15
Amount awarded: 2 589 600 PLN
Project start date (Y-m-d): 2021-12-15
Project end date (Y-m-d): 2025-12-14
Project duration:: 48 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- The Therapeutic Potential of the Restoration of the p53 Protein Family Members in EGFR-Mutated Lung CancerAuthors:Fregni M, Ciribilli Y, Zawacka-Pankau JE.Academic press:Int J Mol Sci. (rok: 2022, tom: 23(13):7213, strony: 20), Wydawca: MDPIStatus:PublishedDOI:10.3390/ijms23137213 - link to the publication